New patented product combines olive tree polyphenols and triterpenes to provide chronic inflammation control and improve gut function 

Natac Group (NAT), a biotechnology company specializing in the sustainable production of botanical extracts and omega-3 oils with proven health benefits, has presented its new Branded Ingredient, Oligut, at Vitafoods Europe, the nutraceutical industry exhibition held in Barcelona. 

This new patented product combines olive tree polyphenols and triterpenes to improve gastrointestinal health and reduce the inflammation that causes many digestive disorders and the onset of diseases such as irritable bowel syndrome (IBS). 

Preclinical in vivo and in vitro studies have demonstrated Oligut’s efficacy in reducing inflammation, strengthening the intestinal barrier, improving the microbiota and intestinal immune balance, among other aspects. 

‘The unique combination of olive compounds offers specific support for intestinal health while reinforcing overall wellbeing’, explains Esther de la Fuente, Natac’s scientific director. She adds: ‘With Oligut, we go one step further in our mission to offer natural and effective solutions backed by scientific evidence that respond to today’s consumer needs’. 

Oligut can be applied in different formats, from pills to gummies, capsules, or sticks, among others. This brings to nine the number of Branded Ingredients that make up Natac’s portfolio and which are aimed at the nutraceutical and animal feed sectors. 

About Natac Group 

Natac Group is a leading biotechnology company specialising in the sustainable production of botanical extracts and omega-3 oils with proven health benefits. Natac researches, develops, manufactures, and markets natural ingredients for use in food supplements, pharmaceuticals, functional foods, animal nutrition, and cosmetics. It has three production plants and two sales offices in the USA and Singapore. The group has an extensive product portfolio -it has developed more than 180 products- and has 

executed more than 40 national and European R&D&I projects. Natac was listed on the BME Growth in the third quarter of 2023, marking the second-largest capital increase in the history of the BME.